These Melanoma Patients Got a Vaccine Made for Their Own Tumors. 2 Years Later, 82% Are Still Cancer-Free

82% cancer-free at two years, and the stocks fell. Wall Street has priced the cure and found it cheaper than the treatment.

An apparent leak prompted Merck and Moderna to release the full trial results ahead of schedule, but investors puzzlingly greeted the good news by sending the companies’ stock prices down.

Read it at Gizmodo ↗

← Front page